- Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
For: Early Breast CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
This study looks at a new drug, giredestrant, with an existing drug, everolimus, for advanced breast cancer. It compares this combination to standard hormone therapy plus everolimus, for people whose cancer has grown despite previous treatments.
For: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Germany - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
This study looks at a new drug, giredestrant, for advanced breast cancer that's grown despite previous treatments. It compares giredestrant to standard hormone treatments to see if it's safe and works better for patients with ER-positive, HER2-negative cancer.
For: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
For: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
For: Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Belgium - RecruitingPHASE2
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
This study looks at new treatments for HR-positive/HER2-negative breast cancer that has been surgically removed. It uses blood tests to find tiny traces of cancer that might come back. If found, patients may get new drug combinations to see if they can stop the cancer from returning.
For: Breast CancerSpain · United Kingdom - RecruitingPHASE1, PHASE2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
This study is looking at new treatments for advanced breast cancer. It tests a new drug called GDC-4198, alone or with giredestrant, and compares it to another combination (abemaciclib + giredestrant). The aim is to find safer and more effective ways to treat this type of cancer.
For: Breast CancerUnited States · Australia · Brazil - RecruitingPHASE3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is testing a new drug, giredestrant, against a standard treatment for advanced breast cancer. It's for people whose cancer has grown resistant to previous hormone therapy, to see if giredestrant, combined with other drugs, works better and is safe.
For: Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada